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ABSTRACT
Familial hypercholesterolemia (FH) is an
inherited disorder of lipid metabolism
characterized by premature cardiovascular
disease. It is one of the most common
metabolic disorders affecting humans. There
are two clinical manifestations: the milder
heterozygous form and more severe
homozygous form. Despite posing a significant
health risk, FH is inadequately diagnosed and
managed. As the clinical outcome is related to
the degree and duration of exposure to elevated
low-density lipoprotein cholesterol (LDL-C)
levels, early treatment is vital. Diagnosis can
usually be made using a combination of clinical
characteristics such as family history, lipid
levels, and genetic testing. Mutations in the
gene encoding the LDL receptor (LDLR),
apolipoprotein B, the pro-protein convertase
subtilisin/kexin 9 (PCSK9), and LDLR adaptor
protein are the commonest abnormalities. Early
identification and treatment of patients, as well
as screening of relatives, helps significantly
reduce the risk of premature disease. Although
statins remain the first-line therapy in most
cases, monotherapy is usually inadequate to
control elevated LDL-C levels. Additional
therapy with ezetimibe and bile acid
sequestrants may be required. Newer classes of
pharmacotherapy currently under investigation
include lomitapide, mipomersen, and
monoclonal antibodies to PCSK9. Lipoprotein
apheresis may be required when multiple
pharmacotherapies are inadequate, especially in
the homozygous form. Effective early detection
and treatment of the index individual and
initiation of cascade screening will help reduce
the complications associated with FH. In this
article,we review thedisease of FH, complexity of
diagnosis and management, and the challenges
faced inpreventing the significantmorbidity and
mortality associated with it.
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INTRODUCTION
Familial hypercholesterolemia (FH) is an
inherited autosomal dominant disorder of
premature atherosclerosis [1]. It was first
described in the late 1930s by Carl Mt‹ ller, a
Norwegian clinician in a landmark paper by
putting forward the idea that
hypercholesterolemia and tendinous
xanthomas were linked to cardiovascular (CV)
disease through a single gene inheritance [2].
The clinical phenotype was further
characterized in 1964 into the mild
heterozygous (HeFH) and more severe
homozygous (HoFH) forms with dominant
inheritance [3]. While Dr Mt‹ ller had initially
postulated that causal and prophylactic
intervention may be beneficial, it was almost
50 years before this became a possibility.
Historically, untreated HeFH begins to
manifest its clinical consequences in the
fourth decade in men and fifth decade in
women. Patients with HoFH, however, may
suffer significant CV events as early as in the
first decade of life. By early adulthood, these
patients without treatment have 100 times
greater mortality risk from CV disease resulting
from coronary atherosclerosis or supra-vascular
aortic valve calcification as compared to those
without FH [1]. In general, those with HoFH do
not survive past 30 years without therapeutic
interventions [1]. Ever since the work of
Goldstein and Brown in 1983, it had been
generally accepted that FH has a population
prevalence of 1:500 in HeFH and 1:1,000,000 in
HoFH [4]. These figures, however, vastly
underestimate the true prevalence. Recent
work by the European Atherosclerosis Society
(EAS) noted widening inconsistency of
diagnosis, with 71 % of patients with FH
diagnosed in Netherlands, 43 % in Norway,
and only 6 % in Spain [5]. In addition, these
figures were only obtainable for 22 countries
out of approximately 200 in the world. Despite
posing a significant health and economic
burden, the true prevalence is yet to be
accurately determined. Data suggest that HoFH
may actually affect 1 in 160,000–300,000 people
[6]. The Copenhagen General Population Study
and EAS estimate an HeFH prevalence of 1:200
instead of the historical 1:500, which would
mean that between 14 and 34 million
individuals may in fact be affected worldwide
[5]. This represents a staggering number whose
risk may be easily reduced with lipid-lowering
therapy, yet are currently being overlooked.
In this article, we review the disease of FH,
complexity of diagnosis and management, and
the challenges faced in preventing the
significant morbidity and mortality associated
with it. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
PATHOPHYSIOLOGY
Abnormal elevations in plasma low-density
lipoprotein cholesterol (LDL-C) in FH are
largely due to functional genetic mutations in
the LDL receptor (LDLR), and less frequently
apolipoprotein B (ApoB) or gain-of-function
mutations of pro-protein convertase subtilisin/
kexin 9 (PCSK9). Autosomal recessive FH is
associated with LDLR-adaptor protein (LDLRAP)
mutation [1]. These mutations mainly result in
four molecular defects: failed internalization of
bound LDL, reduced LDL binding, lack of
receptor expression, and failure of LDLR to
reach the plasma membrane [7]. Hepatocyte
and peripheral cell-regulated endocytosis of
LDL-C occurs via ApoB, a protein that
transports lipids through the lymphatic and
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circulatory system. Genetic mutation of ApoB
leads to decreased LDL affinity for the LDLR and
reduced hepatic LDL plasma clearance. FH is
also associated with raised levels of lipoprotein
(a) [Lp(a)] by an unknown mechanism [8].
Lp(a) levels are higher in HoFH than HeFH.
Defective high-density lipoprotein (HDL)-
driven cholesterol efflux may also be
associated with low levels of HDL cholesterol
in HoFH [8]. If FH is inadequately treated or
untreated, it leads to cholesterol retention in
the arterial wall with foam cell formation
within the intima, accelerated occlusive
atherosclerosis, and early CV disease [5, 9].
HeFH is characterized by only one normal
allele and may be due to loss-of-function LDLR
mutation, gain-of-function mutation in PCSK9,
or mutations in ApoB affecting the LDLR-
binding domain [5]. To date, more than 1200
LDLR mutations are documented in this gene
[9]. HoFH, on the other hand, is relatively rare
with patients having two mutant copies of the
gene, with impaired LDLR function being the
most common and associated with devastating
clinical consequences. Other variations of the
clinical HoFH phenotype include compound
heterozygotes with mutations at two different
sites of the same gene or double heterozygotes,
for example having one copy of ApoB gene
defect and one copy of an LDL-R defect.
CLINICAL PRESENTATION
AND DIAGNOSIS
In the primary care setting, the diagnosis of FH
may be easily missed. Patients are commonly
only identified after experiencing a CV event at
an unexpected age or as a result of a family
member being diagnosed. HoFH is likely when
LDL-C levels are greater than 13 mmol/L
(500 mg/dL) in adults and 11 mmol/L
(420 mg/dL) in children [10]. Triglyceride (TG)
levels may remain normal [11]. LDLR-negative
HoFH patients usually have a worse prognosis,
succumbing to complications by the second
decade [6]. In addition to cholesterol levels,
diagnosis may be supported by features seen
during physical examination such as tendon
xanthomas on the dorsal aspect of the
metacarpophalangeal joints or at the calcaneal
tendon, and arcus senilis. The EAS diagnostic
criterion for HoFH is outlined in Table 1 [12].
For early effective prevention of CV disease,
HeFH should be suspected in asymptomatic
individuals with elevated plasma total
cholesterol (TC) or LDL-C concentrations,
relevant clinical history, physical signs, or a
family history of premature coronary disease.
TC levels greater than 6.7 mmol/L (260 mg/dL)
and 7.5 mmol/L (290 mg/dL)—or untreated
LDL-C levels greater than 4 mmol/L (155 mg/
dL) and 4.9 mmol/L (190 mg/dL)—warrant
further investigation in children and adults,
respectively, after exclusion of secondary causes
of hypercholesterolemia such as diabetes,
hypothyroidism, and obesity [5, 13].
Although clinical and biochemical findings
provide valuable diagnostic information,
specialized genetic testing is often required.
With the advent of DNA-based mutation
screening methods, direct detection of
mutations in the LDLR, ApoB, PCSK9, and
LDLRAP genes are now widely utilized.
However, it is reported that up to 40 % of
patients with a clinical diagnosis may in fact
not have a genetic diagnosis of their
hyperlipidemia [14, 15]. This may be due to
causal mutations yet to be discovered,
insensitivity of current testing, or even
misdiagnosis using the biochemical and
clinical criteria. The National Institute for
Health and Care Excellence (NICE) guidelines
in the United Kingdom (UK) recommend
referral to an FH specialist post-diagnosis for
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initiation of cascade testing [10]. Cascade
testing allows identification of people at risk
by the process of family tracing, using LDL-C
levels and/or a DNA test if the mutation has
already been identified in the index individual/
proband. DNA-positive relatives identified
through cascade screening may not have
elevated LDL-C levels and not fulfill the
clinical diagnostic criteria [5, 15, 16]. This
raises a complex dilemma of treating without
elevation of LDL-C levels. On balance, due to
the lifetime exposure and risk, lipid-lowering
therapy should be considered and ultimately
decided with the patient themselves.
To date, however, there is no single
internationally accepted criterion for the
diagnosis of FH. The three most commonly
used and validated diagnostic tools are the
Simon Broome Register in the UK, the Dutch
Lipid Clinic Network criteria, and the United
States (US) Make Early Diagnosis to Prevent
Early Death (MEDPED) [17–19]. The Simon
Broome and the Dutch criteria take into
account the family history, clinical history,
physical signs, LDL-C concentration, and
molecular genetic testing results to classify the
likelihood of FH. The main difference between
the two being that the Simon Broome criteria
recognizes DNA evidence of a mutation as
evidence of definite FH, while the Dutch
require one other criteria to be met in
addition to the molecular diagnosis for
definite FH. All three systems also use different
age cutoffs for defining premature coronary
heart disease (CHD). The US MEDPED criterion
uses age-specific thresholds of TC concentration
to diagnose FH with TC cutoff levels being lower
in the first-, second- and third-degree relatives
than the general population. The main
disadvantages of its use are that clinical
characteristics and FH-associated gene
mutation are not considered.
TREATMENT
The goal of treatment in FH is to reduce the
risk of atherosclerotic heart disease. All patients
with FH, whether heterozygous or
homozygous, should undergo a
comprehensive program of lifestyle
modification. This has three primary
objectives: dietary changes, exercise and
behavioral therapy [13]. Dietary changes
include reduction in saturated fats, transfats,
and cholesterol. Referrals should be made to a
nutritionist and smoking cessation encouraged.
Risk factors such as hypertension, diabetes, and
smoking should be addressed. Although these
measures are of benefit, they are unlikely to
lower the LDL-C levels sufficiently and direct
intervention is invariably needed to reduce the
levels.
Table 1 The diagnostic criteria of homozygous familial
hypercholesterolemia (adapted from the European
Atherosclerosis Society guidelines) [5]
(a) Two mutant alleles at the LDLR, ApoB, PCSK9, or
LDLRAP1 gene locus
OR
(b) Untreated LDL-C[13 mmol/L (500 mg/dL) or
treated LDL-C C 8 mmol/L (300 mg/dL)
PLUS
(c) Cutaneous or tendon xanthoma before 10 years of
age
OR
(d) Untreated raised LDL-C levels as per diagnostic
criteria in both parents
For diagnosis: (a)/(b) plus (c) OR (d) alone
ApoB Apolipoprotein B, LDL-C Low-density lipoprotein
cholesterol, LDLR Low-density lipoprotein receptor,
LDLRAP Low-density lipoprotein receptor-adaptor
protein, PCSK9 Pro-protein convertase subtilisin/kexin 9
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Treatment for HeFH
To date, no randomized controlled trials have
been conducted assessing the benefit of lipid-
modification treatment on CHD events among
patients with HeFH. As such, much of the
pharmacotherapy currently used is based on an
extrapolation of data among non-FH patients or
from a few observational studies conducted
principally using hydroxymethylglutaryl co-
enyzme A (HMG CoA) reductase inhibitors
(statins) in patients with FH [20, 21]. Statins
remain the only class of lipid-lowering therapy
to reduce total and coronary mortality post-
myocardial infarction. It is widely accepted that
maximal potent statin dose should be initiated
as first-line therapy in adults post-diagnosis of
HeFH [5]. If started prophylactically in early
adulthood, statin use has been shown to lower
the risk of CHD by up to 80 % [20]. NICE
recommends a target of 50 % reduction in LDL-
C concentration [22]. In accordance with the
European Society of Cardiology, the EAS has
outlined new LDL targets [5]:
• children\3.5 mmol/L (\135 mg/dL);
• adults\2.5 mmol/L (\100 mg/dL);
• adults with CHD or diabetes\1.8 mmol/L
(\70 mg/dL).
Although the 2013 American College of
Cardiology/American Heart Association
Guidelines do not recommend a target LDL
level, high-intensity statin therapy is
recommended in asymptomatic arteriosclerotic
CV disease (ASCVD) with LDL-C levels greater
than 190 mg/dL where tolerated [23]. Due to its
net benefit in terms of reduction in ASCVD risk
versus potential adverse effects, statin therapy is
recommended for those at increased risk.
Despite maximal dose statin therapy, LDL-C
levels may yet remain elevated. The addition of
ezetimibe (a cholesterol absorption inhibitor) to
statins or as monotherapy reduces CVD events
with NICE and EAS both recommending its co-
administration, which may help reduce LDL-C
levels by 60 to 70 % in total [18, 21]. Results
from the recent Improved Reduction of
Outcomes: Vytorin Efficacy International
Trial (IMPROVE-IT; ClinicalTrials.gov
#NCT00202878) presented at the American
Heart Association 2014 Scientific Sessions have
demonstrated modest benefit with combined
use of ezetimibe and simvastatin in stable
patients post-acute coronary syndrome (ACS)
[72]. Significant reduction in the primary end
point—a composite of CV death, major
coronary events, and stroke—by 6.4 %
compared to monotherapy with statins was
noted (P = 0.016). The absolute risk reduction
was 2 %. Ezetimibe may also be used as
monotherapy in patients unable to tolerate
statins.
Bile acid sequestrants, such as
cholestyramine, colestipol, or colesevelam,
may be added as a third agent in very high-
risk patients with CHD, type 2 diabetes, or LDL-
C levels greater than 1.8 mmol/L ([70 mg/dL)
[18]. Colesevelam is preferred due to its lower
gastrointestinal side effect profile than
cholestyramine and colestipol, both of which
are also associated with poor patient
compliance and significant multi-drug
interactions [24].
Despite a lack of evidence of the clinical
benefit of niacin co-administration, high-dose
therapy has until recently been recommended,
especially in the USA and Canada where its use
had doubled [23, 25, 26]. Its availability in
Europe has started to decline due to two
recently published neutral CVD outcome
studies. The AIM-HIGH (ClinicalTrials.gov
#NCT00120289) study was prematurely
stopped at 3 years due to a lack of clinical
benefit of niacin therapy when compared to
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placebo in patients with established CV disease
who were already being treated with statins and
ezetimibe [27]. One of the criticisms of the
study was that it was not powered to determine
a difference in CV events. The recent
randomized, placebo-controlled HPS2-THRIVE
(ClinicalTrials.gov #NCT00461630) trial
attempted to address this by recruiting 25,673
patients with atherosclerotic vascular disease
and also found no benefit of the addition of
niacin therapy to statin-based LDL-C-lowering
therapy on major vascular events [28]. Quite
worryingly, serious adverse effects were noted
involving the gastrointestinal, musculoskeletal,
and cutaneous systems. In a subgroup analysis,
there was a trend toward improved outcomes in
patients with a high baseline LDL (C58 mg/dL).
Routine administration of niacin should be
curtailed, although it may still have a role in
very select statin-intolerant patients at high risk
of CV events who are unable to reduce LDL-C
levels optimally despite multiple therapies. This
decision should ultimately be made by
specialized clinicians with expertise in
dyslipidemia.
Although the mechanism of action of fibric
acid is not fully understood, its effect is thought
to be due to b-oxidation of fatty acids in
peroxisomes and mitochondria. Fibrates
reduce plasma TG and cholesterol levels, while
elevating HDL-C levels [29]. Due to the
increased risk of myopathy, rhabdomyolysis,
and liver impairment when co-administered
with statins, fibrate use should be restricted to
patients with raised TG levels ([4.5 mmol/L or
170mg/dL) and low HDL levels only [30]. A
recent meta-analysis, however, showed that
neither niacin nor fibrate treatment reduced
all-cause mortality, CHD mortality, myocardial
infarction, or stroke in patients already treated
with statins [31].
Patients with very high CV risk, whose LDL-
C levels remain elevated despite combination
therapies, may be candidates for weekly or bi-
weekly adjunctive lipoprotein apheresis,
especially if there is evidence of progression of
disease. LDL-C and Lp(a) levels may be reduced
by 50–75 % and, while effective, availability of
this service, high costs, and the inconvenience
and invasive nature of this treatment (use
of peripheral veins and, occasionally,
requirement of a fistula) limit its widespread
use [5, 32, 33].
Treatment for HoFH
All patients with HoFH should be initiated on
lipid-lowering therapy as early as possible, with
LDL-C targets the same as in HeFH [6]. Statins
remain the cornerstone of treatment with the
observed benefit due to inhibition of hepatic
lipoprotein synthesis, up-regulation of LDLR, or
an increase in trans-intestinal cholesterol
excretion [34]. While no randomized
controlled trials have been conducted looking
at the end point of CV mortality in HoFH,
statins in the non-FH population are known to
reduce the incidence of major vascular events in
primary prevention, with intensive regimens
producing greater reduction than less intensive
regimens [35, 36]. In HoFH, observational
studies show a dose-dependent effect on LDL-
C reduction and maximum tolerable doses
should generally be prescribed [37, 38]. The
degree of reduction is however less than that
seen in HeFH. Although individual response
may be variable, LDLR-defective patients may
achieve LDL-C reduction of 25 %, while LDLR-
negative patients achieve around 15 %, thus
suggesting that some receptor function is
needed for clinical benefit [6, 39, 40]. Despite
this, statin monotherapy does not reduce LDL-C
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levels sufficiently and co-administration of
ezetimibe is often necessary, yielding a further
15–20 % reduction [41].
Medical therapy with statins alone or in
combination with other lipid-lowering agents
such as ezetimibe, bile acid sequestrants, niacin,
or probucol rarely provide an adequate
solution, and the majority of patients
ultimately require LDL apheresis. In the late
1970s unselective plasmapheresis was used in
patients with HoFH in an attempt to control
hypercholesterolemia, slow coronary
atherosclerosis, and prolong survival with
limited success [42, 43]. Subsequently, work
began to focus on removing LDL more
selectively [44, 45]. Due to its dramatic
benefits, extracorporeal removal of LDL-C by
lipoprotein apheresis is now the treatment of
choice in HoFH. Despite being expensive, time-
consuming, and not readily available, the
substantial benefits of single treatment
reducing LDL-C levels by up to 70 % have
been recommended by the EAS and make it
cost-effective overall [12].
Liver transplantation was first described in
1983 and has now emerged as the most effective
treatment, markedly improving LDL-C levels
long term [46, 47]. Surgery provides a liver with
functional LDLRs, thereby correcting the
molecular defect. It is indicated in patients
who despite maximal medical therapy and
apheresis fail to reduce LDL-C levels
sufficiently. Although successful, it poses
significant challenges including procedure-
related morbidity and mortality, lack of
available donors, and the need for long-term
immunosuppression [48]. Although effective,
transplantation is not a realistic option for
many patients. Due to the limitations of
existing therapies, novel lipid-lowering agents
are being developed and provide a new avenue
for research for the management of FH.
Newer Therapies for FH
Lomitapide
Microsomal TG transfer protein (MTP) localized
on the endoplasmic reticulum is an intracellular
lipid-transfer protein essential for the assembly
and secretion of ApoB-containing chylomicrons
and very low-density lipoproteins (VLDL) in the
intestines and liver [49]. The concept that
pharmacological inhibition of MTP by
lomitapide may reduce LDL-C stemmed from
the discovery that loss-of-function mutation in
the gene encoding MTP results in
abetalipoproteinemia, a rare disorder marked
by hypocholesterolemia with absent ApoB-
containing lipoproteins [50]. Lomitapide binds
to MTP in the liver and intestines, inhibiting
lipid transfer. It was first approved by the US
Food and Drug Administration (FDA) in
December 2012 and the European Medicines
Agency (EMA) as additional therapy to other
lipid-lowering regimes including LDL apheresis
in those aged 18 years and over with HoFH.
In a single-arm, open-label phase 3 study of 29
individuals with HoFH, lomitapide was given as
an adjunct to other therapies including LDL
apheresis [51]. In the intention-to-treat analysis
of all 29 patients, LDL-C reduced by 40 % and
ApoB by 39 % by week 26. In 23 patients who
completed the efficacy phase, lomitapide at
maximal tolerated dose reduced plasma LDL-C
levels by 50 % and ApoB by 49 % from baseline,
although there was considerable variability in the
response to the therapy [49].Apotential andasyet
uncertain consequence is the increase in hepatic
fat during therapy, so serum transaminase levels
should be monitored as ApoB-containing
lipoproteins accumulate in the liver.
Mipomersen
Mipomersen is an antisense oligonucleotide
targeting the messenger ribonucleic acid of
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ApoB with eventual reduction in the secretion
of VLDL [6]. It was approved by the FDA in
January 2013 based on a randomized, double-
blinded, placebo-controlled study of 51 patients
with HoFH [52]. Mipomersen was seen to reduce
LDL-C levels by 25 %, ApoB by 27 %, and
Lp(a) by 31 % when compared to placebo
(stable low-fat diet, pre-existing maximal
tolerated lipid-lowering drugs, and those not
receiving apheresis). However, doubts remain
due to its significant side effects as the EMA
rejected its use in March 2013 [53]. EMA noted
that a high proportion of patients stopped the
drug within 2 years due to liver dysfunction and
there were uncertainties of its effect on long-
term CV outcome. Numerical imbalance in
overall CV events, major adverse cardiac
events, and CV-associated hospitalization
compared to placebo were of considerable
concern [6]. The commonest reason for
discontinuation of mipomersen is injection
site reactions, such as erythema, pain, pruritus,
and local swelling, being seen in around 78 % of
patients [54]. Further evaluation of the long-
term efficacy, outcome, and side effects is
urgently required.
PCSK9 Inhibitors
LDLR is a cell-surface receptor playing a vital role
in regulating the circulating cholesterol levels. It
allows LDL binding with subsequent
endocytosis and lysosomal degradation,
following which it is recycled back to the
plasma membrane [55]. PCSK9 is a serine
protease secreted in the liver and acts by
inhibiting this LDLR recycling with
consequential reduction in LDL clearance.
PCSK9 binds to LDLR resulting in co-
internalization and degradation of the receptor
within the lysosome. This inverse relationship
between plasma PCSK9 levels and LDLR results
in reduced LDL-C metabolism and eventual
hypercholesterolemia [56]. Gain-of-function
mutation in the PCSK9 gene was first
discovered in 2003, linking it to a phenotype
identical to classical FH [57]. What caused
widespread interest was the discovery that loss-
of-function mutation resulted in low plasma
levels of LDL-C and ApoB and thus protection
against CHD events [58]. Since then, several
large epidemiological studies have confirmed
this association. The ARIC study in 2006 showed
that loss-of-function mutations in the PCSK9
gene were associated with lower LDL-C levels in
African Americans (by 28 %) and white
individuals (by 15 %), with consequential
lower risk of coronary events [hazard ratio (HR)
0.11, 95 % confidence interval (CI) 0.02–0.81,
P = 0.03 for African Americans; HR 0.50, 95 %CI
0.32–0.79, P = 0.003 for white individuals] [59].
A 37 mg/dL reduction in LDL-C levels resulting
from these mutations was associated with an
88 % reduction in incident CHD in African
Americans and a 21 mg/dL reduction with a
47 % reduction in white individuals. Analysis of
Copenhagen Heart Studies combined further
supported the notion that PCSK9 mutations
were associated with LDL-C reduction and CHD
events [60]. Combined data from three
Copenhagen studies (prospective, cross
sectional, and case control) showed an LDL-C
reduction of 13 % and risk reduction of 30 % for
ischemic heart disease (IHD) in the mutation
carrier group. Meta-analysis which included
seven general population studies noted 12 %
lower LDL-C levels in carriers compared to non-
carriers [mean LDL difference in fixed effects
model -0.43 mmol/L (95 % CI -0.48 to
-0.38 mmol/L)]. Combined analysis showed
23 % risk reduction in IHD [odds ratio (OR)
0.77 (95 % CI 0.65 to 0.92)] in patients with
PCSK9 mutation compared to non-carriers [60].
Therapeutic inhibition of PCSK9 was first
hypothesized by Berge and colleagues in 2006
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[61]. They reported that specific mutations in
the genome could be associated with
hypocholesterolemia and possibly increase the
response to statin, with additional LDL-C
lowering. This has led to the development of
several new treatments targeting the PCSK9
pathway [6]. Phase 3 trials on monoclonal
antibody therapies are underway and have
yielded promising results so far. In the
MENDEL-2 (ClinicalTrials.gov #NCT01763827)
trial, biweekly and monthly evolocumab
treatment was compared to placebo and
ezetimibe [62]. Biweekly 140 mg evolocumab
treatment reduced LDL-C levels from baseline
by an average of 57 % (95 % CI -59.5 to
-54.6 %), while ezetimibe reduced levels by an
average of 17.8 % (95 % CI -21.0 to -14.5 %).
Monthly treatment with 420 mg evolocumab
reduced levels by 56.1 % (95 % CI -58.3 to
-53.9 %), with ezetimibe reducing by an average
18.6 %(95 %CI-21.6 to-15.5 %). TheGAUSS-2
(ClinicalTrials.gov #NCT01763905) trial
demonstrated similar benefit in patients
intolerant to statins [63]. Mean percent
reductions in LDL-C from baseline with
biweekly evolocumab was 56.1 % (95 % CI
-59.9 to -52.4 %), and with ezetimibe 18.1 %
(95 %CI-23.1 to - 13.1 %).Monthly treatment
showed similar results to the MENDEL-2 trial,
with 52.6 % LDL-C reduction with evolocumab
(95 % CI -55.7 to -49.5 %) and 15.1 % with
ezetimibe (95 % CI -19.3 to
-10.9 %) [62].
The randomized double-blinded placebo-
controlled LAPLACE-2 (ClinicalTrials.gov
#NCT01763866) study found that treatment
with evolocumab reduced LDL-C levels by
66–75 % and 63–75 % versus placebo in
patients already receiving moderate and high-
intensity statin therapy, respectively [64].
Similar results have also been seen in the
DESCARTES-2 (ClinicalTrials.gov
#NCT01516879) trial [65]. In patients with
HoFH, evolocumab therapy caused a
significant reduction in LDL-C by 30.9 %
(95 % CI -43.9 to -18.0 %, P\0.0001) in the
recently published TESLA Part B
(ClinicalTrials.gov #NCT01588496) trial in
patients with LDLR mutations in both alleles
of which at least one was defective [66]. Benefit
has also been noted in patients with HeFH. The
RUTHERFORD-2 (ClinicalTrials.gov #NCT017
63918) trial randomly assigned 331 patients
with HeFH to evolocumab or placebo every 2 or
4 weeks [67]. Being assigned to the monoclonal
antibody resulted in 56–63 % reduction in
LDL-C after 12 weeks in patients already
receiving a statin and 60 % of those who were
taking ezetimibe. These trials have shown
promising results, especially in patients with
high cholesterol who cannot tolerate statins or
where other lipid-lowering therapy does not
reduce the LDL-C levels enough. The long-term
safety of these compounds and very low DL-C
remain unclear and data from larger phase 3 or
4 trials are keenly awaited.
Gene Therapy
The primary defect in 85 % of FH cases is
mutation or deletion of the LDLR-encoding
gene responsible for removing LDL-C via
endocytosis and intracellular degradation [11].
The availability of functional LDLRs post-liver
transplantation in HoFH has provided backing
to the idea that gene replacement may
constitute an important strategy for treatment.
In animal models, viral vector-based gene
transfer has been seen to result in
overexpression of LDLR with long-term
stabilization in hypercholesterolemia [68]. A
pilot study in 1995 in the USA used
recombinant retroviruses in five patients with
HoFH with inconsistent results [69]. Since
then, stepwise technological advances and
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refinements have been made. Gene therapy
using vectors based on serotype 8 of the
adeno-associated virus (AAV8) is one of the
other methods under development [70].
Although it remains at an investigational
stage, gene therapy does provide an exciting
new avenue for future research, especially for
patients with HoFH who are LDL-R defective.
CHALLENGES FACED
BY THE CLINICIAN
Despite the significant progress in our
understanding, FH remains one of the most
poorly diagnosed and managed diseases in the
world. Early detection and management is not
only cost-effective, but also preserves life.
However, achieving this remains a
considerable challenge. The discovery of
elevated blood cholesterol may be
opportunistic or may be sought during cascade
screening of relatives of an affected individual.
Furthermore, a diagnosis of FH should be
considered in cases of premature CHD or
among first-degree relatives or individuals with
premature CHD.
FH is overexpressed among those with CHD
occurring in about 1:10 people with CHD
compared with 1:200–300 of the general
population. While the norm is to initiate high-
intensity statin therapy following an ACS
irrespective of cholesterol levels, it is unlikely
that patients with FH reach LDL-C goals of
70 mg/dL. Several factors make the diagnosis of
FH difficult. Firstly, clinicians do not think
about this and, as cardiology is largely a
procedure-driven specialty and with a drive in
most health-care systems to reduce bed stay, a
detailed family history and an elevated LDL-C
are more likely to be overlooked as compared to
a hemoglobin or a creatinine value post-
percutaneous coronary intervention.
Furthermore, there is a broad spectrum of
LDL-C levels in FH which make this difficult
[71]. There may also be a lack of understanding
of FH among cardiologists in particular and
overconfidence in the benefits of statin therapy.
Most patients are either simply discharged on
moderate or high-intensity statin, cholesterol
levels ignored, or simply left to the patient’s
own general practitioner to investigate further,
who is likely to know less than the cardiologist.
An integrated care pathway where data flows
seamlessly post-ACS to medical personnel
directly involved in the patient’s care would
be one solution, especially if abnormal results
triggered data clinical tasks such as further
investigation or referrals. Efforts should also be
made to ensure that there is a better uptake of a
nurse-led physician-supported cardiac
rehabilitation program where every patient
goes through the system and is adequately
followed up, as abnormal results could be
picked up in the first 3 months post-ACS.
Once a diagnosis of FH is made, focus should
shift to family members, but this seldom occurs.
Most countries do not possess an integrated
system or resources to adequately initiate
cascade screening, where the focus is about
preserving health, rather than treating the
consequences of disease. The organizational
and legislative environments are variable
according to locality. After gaining informed
consent, relatives should be invited to specialist
lipid clinics with plasma cholesterol level
measurement and genetic assessment. Another
challenge is the ability to provide appropriate
psychological support to those being screened,
and especially asymptomatic children. Advice
on contraception and pregnancy needs to be
provided, especially as statins need to be
avoided in a gestating or lactating patient. The
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real challenge in delivering FH care is to have an
effective care model, with an integration of
hospital and community-based services, having
an appropriate informational technology setup,
education and research of not only the patient
but also the physician, and establishing an
appropriate family support group. This would
provide an effective framework for good clinical
practice.
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